Jim Tomlinson

Jim Tomlinson has extensive experience in pharmaceutical sales and territory management, with a career spanning over two decades. Currently a Neuroscience Sales Specialist at Intra-Cellular Therapies since January 2020, Jim successfully launched Caplyta for schizophrenia and bipolar disorders. Previously, Jim held the position of Senior Executive Specialist at Teva Pharmaceuticals, where key achievements included launching Nuvigil and Azilect. With a strong background in primary care and specialized sales across various medical fields, Jim has consistently driven sales growth and developed strategic relationships throughout multiple roles at reputable organizations, including Merck and First Horizon Pharmaceuticals. Jim holds a Bachelor of Science degree in Health and Physical Education from Auburn University.